New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
X4 Pharmaceuticals, Inc.
XFOR
Shape
US Flag

NASDAQ

Unprofitable

Unprofitable

84M

Biotechnology

Next Earning date - 13 Nov 2024

84M

Biotechnology

Next Earning date - 13 Nov 2024

0.50USD
Shape0.01 ( 2.47%)
Market Open
favorite-chart

Relative Strenght

19
favorite-chart

Volume Buzz

-11%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

69%

Quote Panel

Shape
Updated October 28, 2024
1W -1.41 % 1M -25.58 % 3M -42.44 % 1Y -32.05 %

Key Metrics

Shape
  • Market Cap

    83.91M


  • Shares Outstanding

    168.50M


  • Share in Float

    117.20M


  • Dividende

    0


  • Earning Date

    13 Nov 2024


  • Price Target

    0.498


  • Average Volume

    1.07M


  • Beta

    0.357


  • Range

    0.472-1.6


  • Industry

    Biotechnology


  • Website

    https://www.x4pharma.com


  • Sector

    Healthcare


Fundamentals

Shape

N/A

P/E Ratio

22.60x

P/S Ratio

1.03x

P/B Ratio

0.8

Debt/Equity

486.7%

Net Margin

$0.1

EPS

How XFOR compares to sector?

P/E Ratio

Relative Strength

Shape

XFOR

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$44M

Shape7724%

2025-Revenue

$0.47

Shape-204%

2025-EPS

$26M

Shape178%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Cantor Fitzgerald

initialise

Previous: Not converted

2022-12-22

Now: Overweight

Piper Sandler

initialise

Previous: Not converted

2022-12-11

Now: Overweight

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

N/A

-0.26
vs -0.76

Q4.22

arrow
arrow

N/A

-0.29
vs -1.24

Q1.23

arrow
arrow

N/A

-0.16
vs -0.72

Q2.23

arrow
arrow

N/A

-0.33
vs -0.60

Q3.23

arrow
arrow

N/A

-0.01
vs -0.26

Q4.23

arrow
arrow

N/A

-0.10
vs -0.29

Q1.24

arrow
arrow

N/A

-0.26
vs -0.16

Q2.24

arrow
arrow

N/A

-0.07
vs -0.33

Q3.24

arrow
arrow

N/A

-0.17
vs -0.01

Q4.24

arrow
arrow

N/A

-0.16
vs -0.10

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

NA

NA  vs NA

Q4.22

arrow
arrow

NA

NA  vs NA

Q1.23

arrow
arrow

NA

NA  vs NA

Q2.23

arrow
arrow

NA

NA  vs NA

Q3.23

arrow
arrow

NA

NA  vs NA

Q4.23

arrow
arrow

NA

3.1M  vs NA

Q1.24

arrow
arrow

NA

NA  vs NA

Q2.24

arrow
arrow

NA

563K  vs NA

Q3.24

arrow
arrow

NA

1.7M  vs NA

Q4.24

arrow
arrow

+29%

3.9M  vs 3.1M

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

-39%

-0.39
vs -0.71

Q4.22

arrow
arrow

-46%

-0.46
vs -0.39

Q1.23

arrow
arrow

-82%

-0.82
vs -0.46

Q2.23

arrow
arrow

-82%

-0.82
vs -0.82

Q3.23

arrow
arrow

-3%

-0.03
vs -0.82

Q4.23

arrow
arrow

-37%

-0.37
vs -0.03

Q1.24

arrow
arrow

-4997%

-49.97
vs -0.37

Q2.24

arrow
arrow

+96%

0.96
vs -49.97

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

59

59
vs 47

26%

Q4.22

arrow
arrow

56

56
vs 59

-5%

Q1.23

arrow
arrow

61

61
vs 56

9%

Q2.23

arrow
arrow

102

102
vs 61

67%

Q3.23

arrow
arrow

96

96
vs 102

-6%

Q4.23

arrow
arrow

96

96
vs 96

NA

Q1.24

arrow
arrow

103

103
vs 96

7%

Q2.24

arrow
arrow

105

105
vs 103

2%

Earnings Growth

Latest News